Immunogenicity and safety of influenza vaccine in lung cancer patients receiving immune checkpoint inhibitors - Immunogenicity and safety of influenza vaccine in lung cancer patients receiving immune checkpoint inhibitors

Department of Pulmonology, Kameda Medical Center0 sites24 target enrollmentSeptember 28, 2020

Overview

Phase: 未知
Intervention: Not specified
Conditions: Not specified
Sponsor: Department of Pulmonology, Kameda Medical Center
Enrollment: 24
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Influenza vaccination in the 23 patients included in the immunogenicity analyses significantly increased geometric mean titer for all strains, and seroprotection rate, seroresponse rate, and seroconversion rate were 52% to 91%, 26% to 39%, and 26% to 35%, respectively. In the 24 patients included in the safety analyses, 7 (29%) and 5 (21%) patients exhibited systemic and local reactions, respectively. Only one patient (4%) (hypothyroidism, grade 2) showed post-vaccination immune-related adverse events.

Registry

who.int

Start Date

September 28, 2020

End Date

April 15, 2021

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Department of Pulmonology, Kameda Medical Center

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1 Patients who have been vaccinated with influenza vaccine in the 2020/2021 season 2 Patients who have had anaphylaxis due to the components of influenza vaccine, or those who may have allergies 3 Patients with egg allergies 4 Influenza infected patients in 2020/2021 season 5 Patients who suffered from acute febrile illness or other serious illness at the timing of vaccination 6 Those who received a cytotoxic agent within 1 month of vaccination 7 Those who are taking steroids / immunosuppressants (excluding administration as antiemetics) 8 Others who are not suitable for vaccination